Search

Your search keyword '"Van Bruwaene S"' showing total 17 results
Start Over Author "Van Bruwaene S" Journal european urology open science
17 results on '"Van Bruwaene S"'

1. Is cystoscopic sphincter evaluation a reliable witness before continence surgery? A prospective, blinded, real life, single centre study

Author

Tutolo, M., primary, Rosiello, G., additional, Cristodoro, M., additional, Bruyneel, L., additional, De Ridder, D., additional, Beels, E., additional, Heesakkers, J., additional, Everaert, K., additional, Kasyan, G., additional, Van Bruwaene, S., additional, Geavlete, B., additional, Ammirati, E., additional, Barletta, F.M., additional, Cannoletta, D., additional, Scuderi, S., additional, Salonia, A., additional, Briganti, A., additional, and Van der Aa, F., additional

Published
2021
Full Text
View/download PDF

2. SATURN: A European, Prospective, Multicentre Registry for Male Stress Urinary Incontinence Surgery

Author

Van der Aa, F., Everaert, K., Van Renterghem, K., Van Bruwaene, S., De Wachter, S., Zachoval, R., Hüsch, T., Queissert, F., Fisch, M., Martinez-Salamanca, J., Romero-Otero, J., Castro Diaz, D., Puche-Sanz, I., Gago, J., Lledó, E., Arlandis, S., Poblador, A. Fraile, Hoyuela, A. Romero, Gómez de Vicente, J.M., Tikkinen, K.A.O., Hamid, R., Thiruchelvam, N., Sahai, A., Sacco, E., Heesakkers, J., Martens, F., De Kort, L., Nilsen, O.J., Pedersen, J.M., Martens, Frank, Heesakkers, John, Van der Aa, Frank, Thiruchelvam, Nikesh, Witjes, Wim, Caris, Christien, Kats, Joni, and Hamid, Rizwan

Published
2023
Full Text
View/download PDF

3. The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: a retrospective analysis of a contemporary series

Author

Marchioni, M., primary, Campi, R., additional, Minervini, A., additional, Klatte, T., additional, Kriegmair, M.C., additional, Erdem, S., additional, Capitanio, U., additional, Roussel, E., additional, Albertsen, M., additional, Heck, M., additional, Porpiglia, F., additional, Van Bruwaene, S., additional, Linares, E., additional, Hevia, V., additional, Musquera, M., additional, Darweesh, I., additional, Autorino, R., additional, Pavan, N., additional, Antonelli, A., additional, Rubio-Briones, J., additional, Veccia, A., additional, Checcucci, E., additional, Claps, F., additional, and Mir, C., additional

Published
2020
Full Text
View/download PDF

5. Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry

Author

Campi, R., primary, Marchioni, M., additional, Roussel, E., additional, Capitanio, U., additional, Klatte, T., additional, Kriegmair, M., additional, Erdem, S., additional, Rubio-Briones, J., additional, Minervini, A., additional, Heck, M., additional, Porpiglia, F., additional, Van Bruwaene, S., additional, Linares, E., additional, Hevia, V., additional, Musquera, M., additional, Derweesh, I., additional, Autorino, R., additional, Pavan, N., additional, Antonelli, A., additional, Palumbo, C., additional, Guruli, G., additional, Ghali, F., additional, Amiel, T., additional, and Mir, M., additional

Published
2020
Full Text
View/download PDF

6. Predictors for perioperative complications in cytoreductive nephrectomy: Analysis of the registry for metastatic RCC (REMARCC)

Author

Roussel, E., primary, Campi, R., additional, Minervini, A., additional, Kriegmair, M., additional, Heck, M., additional, Klatte, T., additional, Kara, Ö., additional, Bertolo, R., additional, Erdem, S., additional, Capitanio, U., additional, Van Bruwaene, S., additional, Albersen, M., additional, Linares, E., additional, Antonelli, A., additional, Rubio, J., additional, Pavan, N., additional, Autorino, R., additional, Derweesh, I., additional, Musqueara, M., additional, Hevia, V., additional, Porpiglia, F., additional, Ouzaid, I., additional, and Mir, M.C., additional

Published
2020
Full Text
View/download PDF

7. Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score

Author

Mir Maresma, M.C., primary, Marchioni, M., additional, Campi, R., additional, Minervini, A., additional, Kriegmair, M., additional, Heck, M., additional, Porpiglia, F., additional, Van Bruwaene, S., additional, Linares, E., additional, Hevia, V., additional, Musquera, M., additional, Derweesh, I., additional, Ghali, F., additional, Autorino, R., additional, Veccia, A., additional, Roussel, E., additional, Albertsen, M., additional, Pavan, N., additional, Antonellia, A., additional, Palumbo, C., additional, Capitanio, U., additional, Klatte, T., additional, Erdem, S., additional, and Rubio-Briones, J., additional

Published
2020
Full Text
View/download PDF

8. Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry

Author

Meagher, M.F., primary, Mir, M., additional, Rubio, J., additional, Campi, R., additional, Minervini, A., additional, Kriegmair, M., additional, Heck, M., additional, Van Bruwaene, S., additional, Linares, E., additional, Hevia, V., additional, Musquera, M., additional, D’anna, M., additional, Ghali, F., additional, Patel, D., additional, Bradshaw, A., additional, Autorino, R., additional, Guruli, G., additional, Rousel, E., additional, Albertsen, M., additional, Pavan, N., additional, Claps, F., additional, Antonelli, A., additional, Palumbo, C., additional, Marchioni, M., additional, and Derweesh, I., additional

Published
2020
Full Text
View/download PDF

11. Proposal for a two-tier re-classification of stage IV/M1 renal cell carcinoma into M1 (oligometastatic) and M2 (polymetastatic) sub stages

Author

Meagher, M.F., primary, Mir, M., additional, Rubio, J., additional, Campi, R., additional, Minervini, A., additional, Mari, A., additional, Kriegmair, M., additional, Heck, M., additional, Amiel, T., additional, Van Bruwaene, S., additional, Porpiglia, F., additional, Checcucci, E., additional, Linares, E., additional, Hevia, V., additional, Musquera, M., additional, Bradshaw, A., additional, Ghali, F., additional, Patel, D., additional, Autorino, R., additional, Rousel, E., additional, Pavan, N., additional, Antonelli, A., additional, Marchioni, M., additional, McKay, R., additional, and Derweesh, I., additional

Published
2020
Full Text
View/download PDF

13. SC177 - The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: a retrospective analysis of a contemporary series

Author

Marchioni, M., Campi, R., Minervini, A., Klatte, T., Kriegmair, M.C., Erdem, S., Capitanio, U., Roussel, E., Albertsen, M., Heck, M., Porpiglia, F., Van Bruwaene, S., Linares, E., Hevia, V., Musquera, M., Darweesh, I., Autorino, R., Pavan, N., Antonelli, A., Rubio-Briones, J., Veccia, A., Checcucci, E., Claps, F., and Mir, C.

Published
2020
Full Text
View/download PDF

15. The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: a retrospective analysis of a contemporary series

Author

Mireia Musquera, Estefania Linares, I. Darweesh, R. Autorino, Riccardo Campi, Matthias Heck, José Rubio-Briones, Andrea Minervini, A. Antonelli, Enrico Checcucci, Tobias Klatte, Carmen Mir, U. Capitanio, M. Albertsen, Eduard Roussel, Maximilian C. Kriegmair, Nicola Pavan, Michele Marchioni, S. Van Bruwaene, Francesco Claps, Selcuk Erdem, Vital Hevia, Alessandro Veccia, F. Porpiglia, Marchioni, M., Campi, R., Minervini, A., Klatte, T., Kriegmair, M. C., Erdem, S., Capitanio, U., Roussel, E., Albertsen, M., Heck, M., Porpiglia, F., Van Bruwaene, S., Linares, E., Hevia, V., Musquera, M., Darweesh, I., Autorino, R., Pavan, N., Antonelli, A., Rubio-Briones, J., Veccia, A., Checcucci, E., Claps, F., and Mir (, C.

Subjects
Series (stratigraphy), medicine.medical_specialty, business.industry, Urology, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Sarcomatoid Features, Renal cell carcinoma, Retrospective analysis, medicine, Cytoreductive nephrectomy, Radiology, business
Abstract

Introduction: Sarcomatoid features (SF) correlate with worst survival outcomes in patients with primary metastatic renal cell carcinoma (mRCC). Some reports suggested a cut-off above 25% sarcomatoid features as a predictor of poorer outcome. We aimed to report survival outcomes on a large dataset of patients with SF treated with cytoreductive nephrectomy (CN). Materials and methods: A purpose built multi-institutional international database (REgistry of MetAstatic RCC- REMARCC project) was used for this retrospective analysis. Patients with diagnosis of mRCC treated with CN with or without metastasectomy were included. The cohort was stratified according to the presence of SF in the primary specimen. Kaplan Meier methods and Cox proportional Hazards Regression Analyses were used to estimate overall mortality rates. The reverse Kaplan Meier method was used to estimate the median (IQR) follow-up. Results: Overall 617 patients who underwent CN were included. Of all, 78 (12.6%) patients received synchronous/metachronous metastasectomy. A total of 118 (19.1%) patients had SF in the final specimen. The median involvement of the sarcomatoid component was 35.0% (IQR 10.0–72.5%). Patients with SF were more frequently classified as poor prognosis according to Heng’s criteria (44.9 vs. 33.3%, p = 0.022). Moreover, patients with sarcomatoid features harbored more frequently locally advanced disease [pT3-4 stage tumors (88.1 vs. 73.7%, p = 0.003) and pN1 tumors (28.8 vs. 18.22%, p = 0.025)]. The median follow-up was 55.1 (IQR 25.9–120.6) months. Overall, 395 (64.0%) deaths were recorded in the whole cohort. The median overall survival was shorter for patients with SF (13.1 vs. 27.9 months, p < 0.001). However, neither patients with a SF >35% nor those with a SF >50% showed higher overall mortality rates than those with 50% in the specimen was not predictive of higher mortality rates within patients with SF. These results suggest that all patients with a SF on primary tumor should be carefully followed independently of percentage of sarcomatoid dedifferentiation.

Published
2020

16. Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry

Author

M. Albertsen, Nicola Pavan, Mauricio D'Anna, C. Palumbo, Mireia Musquera, Georgi Guruli, Vital Hevia, Michele Marchioni, Maximilian C. Kriegmair, Estefania Linares, E. Rousel, Riccardo Campi, Francesco Claps, Fady Ghali, Margaret Meagher, Matthias Heck, A. Antonelli, Ithaar Derweesh, Maria Carmen Mir, R. Autorino, A. Bradshaw, Andrea Minervini, S. Van Bruwaene, J. Rubio, Devin Patel, Meagher, M. F., Mir, M., Rubio, J., Campi, R., Minervini, A., Kriegmair, M., Heck, M., Van Bruwaene, S., Linares, E., Hevia, V., Musquera, M., D’Anna, M., Ghali, F., Patel, D., Bradshaw, A., Autorino, R., Guruli, G., Rousel, E., Albertsen, M., Pavan, N., Claps, F., Antonelli, A., Palumbo, C., Marchioni, M., and Derweesh, I.

Subjects
Oncology, medicine.medical_specialty, business.industry, Urology, Cancer, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, lcsh:RC254-282, Renal cell carcinoma, Internal medicine, medicine, Overall survival, Metastasectomy, business
Abstract

Introduction & Objectives: As treatment paradigms for management of metastatic renal cell carcinoma (mRCC) have shifted, the role of surgical metastasectomy in management of mRCC has been in similar flux. We examined impact on survival of surgical metastatectomy stratified in the setting of different mRCC risk groups. Materials & Methods: Multicenter retrospective analysis of patients from the REMARCC (REgistry of MetAstatic RCC) database. The cohort was subdivided utilizing Motzer RCC criteria (low, intermediate, and high risk), and impact of metastasectomy was analyzed via multivariable analysis (MVA) and Kaplan Meier analysis within each Motzer subgroup (KMA). Primary outcome was overall survival (OS) and secondary outcome was cancer specific mortality (CSM). Results: 431 patients (59 low risk, 274 intermediate risk, 98 high risk) with median follow-up of 19.2 months were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of low, intermediate and high risk groups (p=0.012). Risk groups differed significantly with respect to ECOG performance status (p

Published
2020
Full Text
View/download PDF

17. AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer.

Author

Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S, Lesage K, Maes A, Üstmert S, Lavent F, Beels L, Grönberg H, Ost P, Lindberg J, and De Laere B

Abstract

Lutetium-177 prostate-specific membrane antigen radioligands ( 177 Lu-PSMA) are new therapeutic agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC). We evaluated the prognostic value of circulating tumour DNA (ctDNA) profiling in patients with mCRPC starting treatment with 177 Lu-PSMA I&T. Between January 2020 and October 2022, patients with late-stage mCRPC ( n  = 57) were enrolled in a single-centre observational cohort study. Genomic alterations in the AR gene, PI3K signalling pathway, TP53, and TMPRSS2-ERG were associated with progression-free survival (PFS) on Kaplan-Meier and multivariable Cox regression analyses. Median PFS of 3.84 mo (95% confidence interval [CI] 3.3-5.4) was observed, and 21/56 (37.5%) evaluable patients experienced a prostate-specific antigen response of ≥50% during treatment. Among 46 patients who provided a blood sample for profiling before 177 Lu-PSMA treatment. ctDNA was detected in 39 (84.8%); higher ctDNA was correlated with shorter PFS. Genomic structural rearrangements in the AR gene (hazard ratio [HR] 9.74, 95% confidence interval [CI] 2.4-39.5; p  = 0.001) and alterations in the PI3K signalling pathway (HR 3.58, 95% CI 1.41-9.08; p  = 0.007) were independently associated with poor 177 Lu-PSMA prognosis on multivariable Cox regression. Prospective evaluation of these associations in biomarker-driven trials is warranted., Patient Summary: We examined cell-free DNA in blood samples from patients with advanced metastatic prostate cancer who started treatment with lutetium-177-PSMA, a new radioligand therapy. We found that patients with genetic alterations in the androgen receptor gene or PI3K pathway genes did not experience a lasting benefit from lutetium-177-PSMA., (© 2023 The Author(s).)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results